Awakening properties of newly discovered highly selective H 3 receptor antagonists in rats

Behavioural Brain Research

Volumn 232, Issue 2, 2012, Pages 416-420

  Griebel, Guy ^a   Decobert, Michel ^a   Jacquet, Agnès ^a   Beeské, Sandra ^a  

^a SANOFI   (France)

Author keywords

Awakening; EEG; Histamine H 3 receptor; Rats

Indexed keywords

6 (3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YLOXY) N METHYLNICOTINAMIDE; ABT 0239; ABT 039; AMPHETAMINE; CIPROXIFAN; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; MODAFINIL; SAR 110068; SAR 110894; TETRAHYDRO PYRAN 4 CARBOXYLIC ACID [2 METHYL 4 (2 METHYL [1,3']BIPYRROLIDINYL 1' YL)PHENYL]AMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AROUSAL; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ELECTROENCEPHALOGRAM; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REM SLEEP; SLEEP WAKING CYCLE; SLOW WAVE SLEEP; THETA RHYTHM;

AMPHETAMINE; ANIMALS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; HISTAMINE H3 ANTAGONISTS; MALE; PYRANS; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, HISTAMINE H3; SLEEP; WAKEFULNESS;

EID: 84861681383     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.04.033     Document Type: Article

References (23)

1. 3-receptor ligands in the cat. Brain Research 1990, 523:325-330.
2. 3 antagonists for treatment of cognitive deficits in CNS diseases. Current Topics in Medicinal Chemistry 2010, 10:153-169.
3. 3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. Journal of Pharmacology and Experimental Therapeutics 2011, 336:38-46.
4. 3 receptor antagonists in dementias. Drug News Perspect 2010, 23:99-103.
5. 3 antagonists as wake-promoting and pro-cognitive agents. Current Topics in Medicinal Chemistry 2008, 8:988-1002.
6. 3 receptors and sleep-wake regulation. Journal of Pharmacology and Experimental Therapeutics 2011, 336:17-23.
7. 3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochemical Pharmacology 2007, 73:1157-1171.
8. -/- mice and patients. Neurobiology of Disease 2008, 30:74-83.
9. Beeské S., Pichat P., Françon D., Hurst W., Gao Z., Avenet P., et al. Awakening properties of newly discovered highly selective H3 receptor antagonists in rats. European Neuropsychopharmacology 2011, 21(Suppl. 3):S262.
10. Guillot E, Pichat P, Diaz JA, Sanchez J, Gonzalez Y, Pruniaux MP, Desvignes C, Texeira S, Bert L, Voltz C, Bergis O, Oury-Donat F, Galzin AM, Griebel G, Avenet P. SAR110894, a novel, potent and selective H3-receptor (H3-R) antagonist: I. binding and functional characterization. Program No 160.21. 2008 Neuroscience Meeting Planner Washington, DC: Society for Neuroscience November 15-19; 2008.
11. Griebel G, Pichat P, Pruniaux MP, Beeské S, Lopez-Grancha M, Genet E, Terranova JP, Castro A, Sánchez JA, Black M, Varty GB, Weiner I, Arad M, Barak S, De Levie A, Guillot E. SAR110894, a potent histamine H3-receptor antagonist, displays procognitive effects in rodents. Pharmacology Biochemistry & Behavior 2012; doi:10.1016/j.pbb.2012.04.004.
12. 3 antagonist. British Journal of Pharmacology 2004, 143:649-661.
13. Ligneau X., Perrin D., Landais L., Camelin J.C., Calmels T.P., Berrebi-Bertrand I., et al. BF2.649 [1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a non-imidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. Journal of Pharmacology and Experimental Therapeutics 2007, 320:365-375.
14. -/- mice. British Journal of Pharmacology 2009, 157:104-117.
15. James L.M., Iannone R., Palcza J., Renger J.J., Calder N., Cerchio K., et al. Effect of a novel histamine subtype-3 receptor inverse agonist and modafinil on EEG power spectra during sleep deprivation and recovery sleep in male volunteers. Psychopharmacology (Berlin) 2011, 215:643-653.
16. Black M, Pichat P, Weiner S, Barak S, Arad M, Delevie A, Varty GB, Bergis O, Griebel G. SAR110894, a novel, potent and selective histamine H3 receptor (H3-R) antagonist: III. Potential activity in positive symptom and cognitive domains of schizophrenia using latent inhibition (LI) models in the rat. Program No 160.19. 2008 Neuroscience Meeting Planner Washington, DC: Society for Neuroscience November 15-19; 2008.
17. Pichat P, Boulay D, Terranova JP, Decobert M, Françon D, Guillot E, Bergis O, Alonso R, Avenet P, Griebel G. SAR110894, a novel, potent and selective H3-receptor (H3-R) antagonist: II. Effects in models predictive of therapeutic activity against cognitive and attention deficits in schizophrenia and ADHD. Program No 160.20. 2008 Neuroscience Meeting Planner Washington, DC: Society for Neuroscience November 15-19; 2008.
18. 3 receptor antagonist with drug-like properties. Journal of Pharmacology and Experimental Therapeutics 2005, 313:165-175.
19. Medhurst A.D., Atkins A.R., Beresford I.J., Brackenborough K., Briggs M.A., Calver A.R., et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. Journal of Pharmacology and Experimental Therapeutics 2007, 321:1032-1045.
20. 3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat. Journal of Neuroscience 2002, 22:7272-7280.
21. 3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats. Biochemical Pharmacology 2007, 73:1182-1194.
22. 3 receptor antagonists. Journal of Pharmacology and Experimental Therapeutics 2008, 325:902-909.
23. Esbenshade T.A., Fox G.B., Krueger K.M., Baranowski J.L., Miller T.R., Kang C.H., et al. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochemical Pharmacology 2004, 68:933-945.